Cargando…

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans

Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp. in recipients of blood and marrow transplantation. Studies using [(14)C]-radiolabeled rezafungin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ong, Voon, Wills, Sarah, Watson, Deborah, Sandison, Taylor, Flanagan, Shawn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765310/ https://www.ncbi.nlm.nih.gov/pubmed/34662192 http://dx.doi.org/10.1128/AAC.01390-21

Ejemplares similares

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
por: Sandison, Taylor, et al.
Publicado: (2017)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
por: Gu, Kenan, et al.
Publicado: (2022)

1400. Mass Balance, Metabolism, and Excretion of [(14)C]-Plazomicin in Healthy Human Subjects
por: Choi, Taylor, et al.
Publicado: (2018)

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
por: Ong, Voon, et al.
Publicado: (2017)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
por: Zhao, Yanan, et al.
Publicado: (2020)

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
por: Nussbaum, Jesse C., et al.
Publicado: (2022)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Absorption, distribution, metabolism, and excretion of [(14)C]‐dasotraline in humans
por: Chen, Yu‐Luan, et al.
Publicado: (2016)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

Pharmacokinetics, Mass Balance, Excretion, and Tissue Distribution of Plasmalogen Precursor PPI-1011
por: Smith, Tara, et al.
Publicado: (2022)

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old
por: Kwara, Awewura, et al.
Publicado: (2018)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax
por: Yamamoto, Brent J., et al.
Publicado: (2016)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
por: Ong, Voon, et al.
Publicado: (2016)

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
por: Kokai-Kun, John F., et al.
Publicado: (2017)

Exploring the Therapeutic Potential of Apigenin in Obesity-Associated Fibrinolytic Dysfunction: Insights From an Animal Study
por: Qadi, Hasan H, et al.
Publicado: (2023)

Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies
por: Watson, James A., et al.
Publicado: (2022)

A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis
por: Connolly, Lynn E., et al.
Publicado: (2018)

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins
por: Garcia-Effron, Guillermo
Publicado: (2020)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
por: El Ghali, Amer, et al.
Publicado: (2023)

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
por: Pfaller, Michael A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cer90tt79oj530v8k7d4je89j0